tetano
Editor, Senior Moderator
Microorganisms
. 2020 Nov 28;8(12):E1885.
doi: 10.3390/microorganisms8121885.
Anti-SARS-CoV-2 Antibody Responses in Convalescent Plasma Donors Are Increased in Hospitalized Patients; Subanalyses of a Phase 2 Clinical Study
Evangelos Terpos[SUP] 1 [/SUP], Marianna Politou[SUP] 2 [/SUP], Theodoros N Sergentanis[SUP] 1 [/SUP], Andreas Mentis[SUP] 3 [/SUP], Margherita Rosati[SUP] 4 [/SUP], Dimitris Stellas[SUP] 4 5 [/SUP], Jenifer Bear[SUP] 6 [/SUP], Xintao Hu[SUP] 6 [/SUP], Barbara K Felber[SUP] 6 [/SUP], Vassiliki Pappa[SUP] 7 [/SUP], Maria Pagoni[SUP] 8 [/SUP], Elisavet Grouzi[SUP] 9 [/SUP], Stavroula Labropoulou[SUP] 3 [/SUP], Ioanna Charitaki[SUP] 1 [/SUP], Ioannis Ntanasis-Stathopoulos[SUP] 1 [/SUP], Dimitra Moschandreou[SUP] 9 [/SUP], Anthi Bouhla[SUP] 7 [/SUP], Stylianos Saridakis[SUP] 10 [/SUP], Eleni Korompoki[SUP] 1 [/SUP], Chara Giatra[SUP] 8 [/SUP], Tina Bagratuni[SUP] 1 [/SUP], Angelos Pefanis[SUP] 11 [/SUP], Sotirios Papageorgiou[SUP] 7 [/SUP], Alexandros Spyridonidis[SUP] 12 [/SUP], Anastasia Antoniadou[SUP] 13 [/SUP], Anastasia Kotanidou[SUP] 14 [/SUP], Konstantinos Syrigos[SUP] 15 [/SUP], Konstantinos Stamoulis[SUP] 16 [/SUP], George Panayiotakopoulos[SUP] 17 18 [/SUP], Sotirios Tsiodras[SUP] 13 18 [/SUP], Leonidas Alexopoulos[SUP] 19 [/SUP], Meletios A Dimopoulos[SUP] 1 [/SUP], George N Pavlakis[SUP] 4 [/SUP]
Affiliations
Abstract
We evaluated the antibody responses in 259 potential convalescent plasma donors for Covid-19 patients. Different assays were used: a commercial ELISA detecting antibodies against the recombinant spike protein (S1); a multiplex assay detecting total and specific antibody isotypes against three SARS-CoV-2 antigens (S1, basic nucleocapsid (N) protein and receptor-binding domain (RBD)); and an in-house ELISA detecting antibodies to complete spike, RBD and N in 60 of these donors. Neutralizing antibodies (NAb) were also evaluated in these 60 donors. Analyzed samples were collected at a median time of 62 (14-104) days from the day of first symptoms or positive PCR (for asymptomatic patients). Anti-SARS-CoV-2 antibodies were detected in 88% and 87.8% of donors using the ELISA and the multiplex assay, respectively. The multivariate analysis showed that age ≥50 years (p < 0.001) and need for hospitalization (p < 0.001) correlated with higher antibody titers, while asymptomatic status (p < 0.001) and testing >60 days after symptom onset (p = 0.001) correlated with lower titers. Interestingly, pseudotype virus-neutralizing antibodies (PsNAbs) significantly correlated with spike and with RBD antibodies by ELISA. Sera with high PsNAb also showed a strong ability to neutralize active SARS-CoV-2 virus, with hospitalized patients showing higher titers. Therefore, convalescent plasma donors can be selected based on the presence of high RBD antibody titers.
Keywords: Covid-19; SARS-CoV-2; antibodies; convalescent plasma; novel coronavirus.
. 2020 Nov 28;8(12):E1885.
doi: 10.3390/microorganisms8121885.
Anti-SARS-CoV-2 Antibody Responses in Convalescent Plasma Donors Are Increased in Hospitalized Patients; Subanalyses of a Phase 2 Clinical Study
Evangelos Terpos[SUP] 1 [/SUP], Marianna Politou[SUP] 2 [/SUP], Theodoros N Sergentanis[SUP] 1 [/SUP], Andreas Mentis[SUP] 3 [/SUP], Margherita Rosati[SUP] 4 [/SUP], Dimitris Stellas[SUP] 4 5 [/SUP], Jenifer Bear[SUP] 6 [/SUP], Xintao Hu[SUP] 6 [/SUP], Barbara K Felber[SUP] 6 [/SUP], Vassiliki Pappa[SUP] 7 [/SUP], Maria Pagoni[SUP] 8 [/SUP], Elisavet Grouzi[SUP] 9 [/SUP], Stavroula Labropoulou[SUP] 3 [/SUP], Ioanna Charitaki[SUP] 1 [/SUP], Ioannis Ntanasis-Stathopoulos[SUP] 1 [/SUP], Dimitra Moschandreou[SUP] 9 [/SUP], Anthi Bouhla[SUP] 7 [/SUP], Stylianos Saridakis[SUP] 10 [/SUP], Eleni Korompoki[SUP] 1 [/SUP], Chara Giatra[SUP] 8 [/SUP], Tina Bagratuni[SUP] 1 [/SUP], Angelos Pefanis[SUP] 11 [/SUP], Sotirios Papageorgiou[SUP] 7 [/SUP], Alexandros Spyridonidis[SUP] 12 [/SUP], Anastasia Antoniadou[SUP] 13 [/SUP], Anastasia Kotanidou[SUP] 14 [/SUP], Konstantinos Syrigos[SUP] 15 [/SUP], Konstantinos Stamoulis[SUP] 16 [/SUP], George Panayiotakopoulos[SUP] 17 18 [/SUP], Sotirios Tsiodras[SUP] 13 18 [/SUP], Leonidas Alexopoulos[SUP] 19 [/SUP], Meletios A Dimopoulos[SUP] 1 [/SUP], George N Pavlakis[SUP] 4 [/SUP]
Affiliations
- PMID: 33260775
- DOI: 10.3390/microorganisms8121885
Abstract
We evaluated the antibody responses in 259 potential convalescent plasma donors for Covid-19 patients. Different assays were used: a commercial ELISA detecting antibodies against the recombinant spike protein (S1); a multiplex assay detecting total and specific antibody isotypes against three SARS-CoV-2 antigens (S1, basic nucleocapsid (N) protein and receptor-binding domain (RBD)); and an in-house ELISA detecting antibodies to complete spike, RBD and N in 60 of these donors. Neutralizing antibodies (NAb) were also evaluated in these 60 donors. Analyzed samples were collected at a median time of 62 (14-104) days from the day of first symptoms or positive PCR (for asymptomatic patients). Anti-SARS-CoV-2 antibodies were detected in 88% and 87.8% of donors using the ELISA and the multiplex assay, respectively. The multivariate analysis showed that age ≥50 years (p < 0.001) and need for hospitalization (p < 0.001) correlated with higher antibody titers, while asymptomatic status (p < 0.001) and testing >60 days after symptom onset (p = 0.001) correlated with lower titers. Interestingly, pseudotype virus-neutralizing antibodies (PsNAbs) significantly correlated with spike and with RBD antibodies by ELISA. Sera with high PsNAb also showed a strong ability to neutralize active SARS-CoV-2 virus, with hospitalized patients showing higher titers. Therefore, convalescent plasma donors can be selected based on the presence of high RBD antibody titers.
Keywords: Covid-19; SARS-CoV-2; antibodies; convalescent plasma; novel coronavirus.